|December 14, 2012|
|10:16 EDT||PODD||Insulet receives 510(k) clearance for next-generation OmniPod insulin pump |
Insulet announced that the company has received 510(k) clearance from the U.S. FDA for the next-generation OmniPod Insulin Management System. The new OmniPod insulin pump is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same 200-unit insulin reservoir capacity and easy-to-use features. In addition to the smaller, lighter Pod, the new OmniPod System includes an updated Personal Diabetes Manager that also features a series of enhancements.
News For PODD From The Last 14 Days
|January 28, 2015|
|09:26 EDT||PODD||Leerink medical devices analyst holds an analyst/industry conference call|
Medical Devices Analyst Antalffy assesses the rapidly-evolving diabetes landscape and the potential growth trajectory for Insulet's OmniPod and DexCom's CGM on an Analyst/Industry conference call to be held on January 29 at 2 pm.
|January 26, 2015|
|10:00 EDT||PODD||On The Fly: Analyst Downgrade Summary|
Subscribe for More Information
|06:53 EDT||PODD||Insulet downgraded to Market Perform from Outperform at William Blair|
William Blair downgraded Insulet to Market Perform citing weaker domestic insulin pump market trends.
|January 21, 2015|
|07:31 EDT||PODD||Insulet well positioned to beat expectations, says Leerink|
Leerink believes the worst is now behind Insulet and that the company is positioned for accelerating new patient adds in Q2 and beyond. Leerink thinks lowered base expectations position Insulet to potentially top forecasts in 2015. The firm lowered its price target for shares to $40 and $50 and keeps an Outperform rating on the name.
|January 16, 2015|
|11:49 EDT||PODD||Insulet sell-off yesterday overdone, says Leerink|
Leerink attributes the sell-off yesterday in shares of Insulet to a downgrade at another firm, which questioned the company's growth in new patient additions. After speaking with management, Leerink thinks that Insulet's patient growth dip in Q1 was heavily influenced by seasonality and that "literally nothing has changed" in terms of end user pump market dynamics. The firm thinks yesterday's pullback was overdone and recommends the shares by bought on the weakness. Leerink maintains its Outperform rating on Insulet, but noted that its model is under review.
|07:48 EDT||PODD||Insulet price target lowered to $39 from $50 at Oppenheimer|
Oppenheimer cut its price target on Insulet after the company reported that the increase in the number of its diabetes patients came in below expectations. The firm thinks the company's FY15 guidance may be conservative, while the company has a number of potential positive catalysts. The firm thinks the stock is in the show-me stage but keeps an Outperform rating on the shares.